225Ac-PSMA-Trillium (BAY3563254) clinical trials

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

This study tests a new treatment, BAY3563254, for advanced prostate cancer that has spread and no longer responds to usual hormone therapy. It aims to find a safe dose and see how well it works by targeting cancer cells with radiation.